论文部分内容阅读
目的:失代偿期乙肝肝硬化患者经过拉米夫定治疗,观察患者临床疗效。方法:选取我院2015年1月-2016年7月收治的乙肝肝硬化患者74例,按照治疗方法不同分为观察组37例,对照组37例,常规方法治疗加上拉米夫定运用于观察组患者,常规方法进行治疗运用于对照组患者,比较两组患者治疗疗效。结果:两组患治疗后对照组患者AST、ALT、TB、ALB及PT指标低于观察组患者,结果有意义(p<0.05)。结论:拉米定夫治疗失代偿期乙肝肝硬化临床效果更加明显,比起传统药物治疗效果更佳,使患者恢复健康时间缩短,值得临床推广使用。
Objective: Decompensated hepatitis B cirrhosis patients after lamivudine treatment to observe the clinical efficacy of patients. Methods: Seventy-four patients with hepatitis B cirrhosis admitted in our hospital from January 2015 to July 2016 were divided into observation group (37 cases) and control group (37 cases). Conventional treatment combined with lamivudine Patients in the observation group were treated with conventional methods in the control group, and the curative effect was compared between the two groups. Results: The indexes of AST, ALT, TB, ALB and PT in the control group were lower than those in the observation group after treatment, with significant results (p <0.05). Conclusion: Lamivudine treatment of decompensated hepatitis B cirrhosis clinical effect is more obvious than the traditional drug treatment better, so that patients with short recovery time, it is worth promoting the use of the clinic.